Dabigatran Etexilate Mesylate is an oral prodrug of dabigatran, a direct competitive thrombin inhibitor used for stroke prevention in non-valvular atrial fibrillation and for venous thromboembolism treatment and prevention. Simson Pharma's Dabigatran Etexilate Mesylate reference standard and impurities support the rigorous stability-indicating testing this high-volume DOAC demands.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Dabigatran Etexilate Mesylate Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.